LOGIN  |  REGISTER
C4 Therapeutics

List of Medical Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 579.37
10.55 1.85
1.24M
381.31M
US$ 220.920B
US$ 113.47
1.97 1.77
5.43M
1.74B
US$ 197.440B
US$ 248.77
0.31 0.12
2.57M
739.70M
US$ 184.020B
US$ 400.10
2.47 0.62
1.37M
354.45M
US$ 141.820B
US$ 358.71
8.33 2.38
778,510
380.26M
US$ 136.400B
US$ 86.92
3.22 3.85
7.89M
1.33B
US$ 115.600B
US$ 68.66
0.72 1.06
3.13M
1.47B
US$ 100.930B
US$ 246.53
4.65 1.92
767,064
288.90M
US$ 71.220B
US$ 539.26
3.17 0.59
392,691
131.41M
US$ 70.860B
US$ 95.16
1.74 1.86
3.00M
601.30M
US$ 57.220B
US$ 139.48
-0.45 -0.32
1.95M
385.52M
US$ 53.770B
US$ 252.57
4.83 1.95
636,333
182.01M
US$ 45.970B
US$ 539.57
8.97 1.69
294,262
83.09M
US$ 44.830B
US$ 147.37
2.96 2.05
1.21M
293.06M
US$ 43.190B
US$ 83.28
0.65 0.79
820,279
493.24M
US$ 41.080B
US$ 196.33
2.15 1.11
564,489
147.09M
US$ 28.880B
US$ 394.10
5.88 1.51
229,153
73.21M
US$ 28.850B
US$ 1.00
20.77 1.58
64,720
21.39M
US$ 28.570B
US$ 112.54
0.94 0.84
1.15M
243.23M
US$ 27.370B
US$ 132.61
4.74 3.71
1.70M
205.08M
US$ 27.200B
US$ 329.50
-0.41 -0.12
535,470
82.50M
US$ 27.180B
US$ 327.90
7.96 2.49
386,757
75.10M
US$ 24.630B
US$ 225.52
4.00 1.81
441,631
98.81M
US$ 22.280B
US$ 138.68
4.88 3.65
902,503
158.90M
US$ 22.040B
US$ 42.69
1.15 2.77
3.69M
507.83M
US$ 21.680B
US$ 345.19
7.09 2.10
422,525
59.20M
US$ 20.440B
US$ 101.84
1.11 1.10
913,607
198.76M
US$ 20.240B
US$ 216.57
3.05 1.43
409,202
84.10M
US$ 18.210B
US$ 77.35
1.18 1.55
1.11M
234.73M
US$ 18.160B
US$ 131.06
2.19 1.70
658,896
110.71M
US$ 14.510B
US$ 269.37
3.93 1.48
257,238
51.35M
US$ 13.830B
US$ 105.41
1.99 1.92
1.19M
123.52M
US$ 13.020B
US$ 93.86
1.46 1.58
319,565
137.67M
US$ 12.920B
US$ 403.27
0.52 0.13
100,292
30.76M
US$ 12.400B
US$ 66.88
1.64 2.51
1.61M
181.53M
US$ 12.140B
US$ 322.61
6.54 2.07
1.41M
37.40M
US$ 12.070B
US$ 169.18
3.66 2.21
971,717
69.93M
US$ 11.830B
US$ 26.34
0.26 1.00
1.15M
437.16M
US$ 11.510B
US$ 90.46
0.46 0.51
1.56M
120.76M
US$ 10.920B
US$ 223.87
7.48 3.46
249,410
47.06M
US$ 10.540B
US$ 184.75
0.91 0.49
387,053
55.77M
US$ 10.300B
US$ 75.15
2.27 3.11
1.14M
128.51M
US$ 9.660B
US$ 42.75
0.05 0.12
910,877
221.36M
US$ 9.460B
US$ 226.38
5.51 2.49
461,955
38.70M
US$ 8.760B
US$ 349.92
9.40 2.76
157,537
23.42M
US$ 8.200B
US$ 144.48
3.83 2.72
489,539
52.91M
US$ 7.640B
US$ 33.31
0.81 2.49
2.01M
207.36M
US$ 6.910B
US$ 213.50
5.23 2.51
356,631
30.30M
US$ 6.470B
US$ 17.21
0.29 1.71
257,898
350.99M
US$ 6.040B
US$ 53.06
1.44 2.79
866,447
112.94M
US$ 5.990B
US$ 92.69
2.99 3.33
431,562
49.47M
US$ 4.590B
US$ 75.46
2.55 3.50
373,775
57.93M
US$ 4.370B
US$ 84.09
2.45 3.00
284,147
50.79M
US$ 4.270B
US$ 60.46
1.71 2.91
651,833
68.55M
US$ 4.140B
US$ 115.06
3.53 3.17
214,558
33.40M
US$ 3.840B
US$ 21.55
0.79 3.81
1.69M
171.55M
US$ 3.700B
US$ 72.63
0.63 0.88
212,973
49.65M
US$ 3.610B
US$ 115.76
0.76 0.66
354,648
30.98M
US$ 3.590B
US$ 48.49
0.18 0.37
637,459
73.71M
US$ 3.570B
US$ 68.90
-0.06 -0.09
1.10M
51.00M
US$ 3.510B
US$ 11.87
0.34 2.95
1.65M
282.83M
US$ 3.360B
US$ 15.46
0.46 3.07
1.04M
216.52M
US$ 3.350B
US$ 59.43
1.04 1.78
289,608
55.77M
US$ 3.310B
US$ 48.26
1.26 2.68
691,193
66.85M
US$ 3.230B
US$ 55.87
1.48 2.72
406,862
53.96M
US$ 3.010B
US$ 23.60
-0.46 -1.91
421,318
124.34M
US$ 2.930B
US$ 47.40
1.29 2.80
1.81M
57.96M
US$ 2.750B
US$ 34.83
1.08 3.20
964,828
78.22M
US$ 2.720B
US$ 48.84
2.41 5.19
335,214
50.96M
US$ 2.490B
US$ 27.79
0.75 2.77
406,750
89.59M
US$ 2.490B
US$ 102.89
2.13 2.11
204,792
24.14M
US$ 2.480B
US$ 80.17
3.08 4.00
350,798
30.78M
US$ 2.470B
US$ 74.12
-0.37 -0.50
582,797
32.72M
US$ 2.430B
US$ 35.30
1.61 4.78
2.18M
65.63M
US$ 2.320B
US$ 17.96
0.27 1.53
2.69M
121.71M
US$ 2.190B
US$ 27.95
1.37 5.15
810,125
76.60M
US$ 2.140B
US$ 34.48
0.73 2.16
477,045
57.82M
US$ 1.990B
US$ 15.20
0.04 0.26
728,755
127.61M
US$ 1.940B
US$ 21.40
-0.09 -0.42
467,210
89.87M
US$ 1.920B
US$ 13.80
0.39 2.91
5.48M
137.98M
US$ 1.900B
US$ 50.67
1.53 3.11
295,598
36.99M
US$ 1.870B
US$ 37.70
1.70 4.72
395,990
48.87M
US$ 1.840B
US$ 21.20
0.53 2.56
686,672
84.26M
US$ 1.790B
US$ 14.64
1.57 12.01
11.92M
107.09M
US$ 1.570B
US$ 11.36
0.08 0.71
835,478
132.91M
US$ 1.510B
US$ 67.20
1.30 1.97
80,550
22.34M
US$ 1.500B
US$ 30.14
1.05 3.61
827,216
47.59M
US$ 1.430B
US$ 50.76
1.06 2.13
250,185
27.20M
US$ 1.380B
US$ 13.25
0.50 3.92
1.45M
98.37M
US$ 1.300B
US$ 7.61
-0.01 -0.13
1.79M
146.96M
US$ 1.120B
US$ 31.87
0.08 0.25
395,048
34.87M
US$ 1.110B
US$ 3.72
0.20 5.68
7.36M
267.95M
US$ 996.770M
US$ 11.91
1.66 16.20
1.00M
82.84M
US$ 986.620M
US$ 39.40
-0.30 -0.76
51,779
23.85M
US$ 939.690M
US$ 19.89
0.30 1.53
102,147
46.20M
US$ 918.920M
US$ 21.62
1.09 5.31
203,942
41.23M
US$ 891.390M
US$ 22.93
1.03 4.70
429,923
38.06M
US$ 872.720M
US$ 6.63
0.34 5.41
500,259
130.82M
US$ 867.340M
US$ 18.46
0.36 1.99
577,548
45.30M
US$ 836.240M
US$ 448.00
10.92 2.50
28,613
1.76M
US$ 788.480M
US$ 2.69
0.05 1.89
1.44M
290.12M
US$ 780.420M
US$ 12.36
0.88 7.67
509,260
61.76M
US$ 763.350M
US$ 1.07
0.06 5.94
11.76M
696.99M
US$ 745.780M
US$ 18.71
-0.32 -1.68
431,821
39.17M
US$ 732.870M
US$ 17.63
0.33 1.91
362,953
40.62M
US$ 716.130M
US$ 1.20
-0.04 -3.23
1.81M
586.80M
US$ 704.160M
US$ 28.97
2.67 10.15
181,722
23.55M
US$ 682.240M
US$ 15.82
0.52 3.40
321,710
41.06M
US$ 649.570M
US$ 21.69
0.06 0.28
166,567
29.78M
US$ 645.930M
US$ 9.50
0.19 2.04
230,835
64.23M
US$ 610.180M
US$ 21.28
-0.31 -1.44
148,349
27.45M
US$ 584.140M
US$ 9.88
0.73 7.98
1.46M
57.73M
US$ 570.370M
US$ 43.37
0.78 1.83
35,790
12.66M
US$ 549.060M
US$ 3.50
0.10 2.94
329,944
156.55M
US$ 547.920M
US$ 10.52
0.95 9.93
728,802
51.78M
US$ 544.730M
US$ 14.29
0.67 4.92
207,043
37.41M
US$ 534.590M
US$ 14.42
0.85 6.26
277,602
36.40M
US$ 524.890M
US$ 8.40
0.15 1.82
150,740
55.08M
US$ 462.670M
US$ 6.14
0.06 0.99
705,141
73.80M
US$ 453.130M
US$ 4.32
-0.02 -0.46
605,723
104.13M
US$ 449.840M
US$ 16.31
0.39 2.45
331,404
27.08M
US$ 441.670M
US$ 16.50
0.51 3.19
104,857
25.71M
US$ 424.220M
US$ 12.58
0.23 1.86
115,270
32.17M
US$ 404.700M
US$ 13.63
0.30 2.25
60,588
28.34M
US$ 386.270M
US$ 17.99
-0.05 -0.28
162,064
20.93M
US$ 376.530M
US$ 13.08
-0.29 -2.17
22,878
28.68M
US$ 375.130M
US$ 15.86
0.40 2.59
108,146
23.60M
US$ 374.300M
US$ 9.38
0.29 3.19
170,454
38.76M
US$ 363.570M
US$ 9.11
0.12 1.33
192,948
38.54M
US$ 351.100M
US$ 7.77
0.22 2.91
284,766
43.21M
US$ 335.740M
US$ 5.16
0.02 0.39
327,680
63.38M
US$ 327.040M
US$ 37.30
0.55 1.50
12,876
8.54M
US$ 318.540M
US$ 0.57
0.01 2.27
1.12M
530.67M
US$ 300.680M
US$ 9.46
-0.04 -0.42
296,602
31.46M
US$ 297.610M
US$ 10.65
0.61 6.08
282,018
25.79M
US$ 274.660M
US$ 7.10
-0.20 -2.74
182,138
36.93M
US$ 262.200M
US$ 5.18
0.15 2.98
79,819
49.55M
US$ 256.670M
US$ 70.18
2.04 2.99
31,356
3.63M
US$ 254.750M
US$ 9.44
0.12 1.29
80,075
26.41M
US$ 249.310M
US$ 2.43
0.06 2.53
590,915
99.17M
US$ 240.980M
US$ 4.73
0.10 2.16
118,217
49.14M
US$ 232.430M
US$ 1.89
0.12 6.78
356,764
121.83M
US$ 230.260M
US$ 6.95
0.35 5.30
186,184
32.91M
US$ 228.720M
US$ 5.70
0.30 5.56
358,861
39.86M
US$ 227.200M
US$ 2.53
0.04 1.41
105,067
82.13M
US$ 207.380M
US$ 8.30
0.15 1.84
33,777
24.43M
US$ 202.770M
US$ 28.55
0.13 0.46
74,331
7.03M
US$ 200.710M
US$ 1.05
0.05 5.00
970,087
181.71M
US$ 190.800M
US$ 8.80
0.29 3.41
36,613
21.20M
US$ 186.560M
US$ 7.97
0.22 2.84
207,803
23.33M
US$ 185.820M
US$ 4.34
0.02 0.46
130,930
42.10M
US$ 182.710M
US$ 4.20
0.18 4.48
76,909
43.40M
US$ 182.280M
US$ 0.51
0.02 4.63
4.76M
315.44M
US$ 161.000M
US$ 1.11
0.05 4.72
349,757
130.11M
US$ 144.420M
US$ 4.80
0.04 0.84
139,839
29.76M
US$ 142.850M
US$ 16.41
0.15 0.92
16,054
8.61M
US$ 141.290M
US$ 1.44
-0.01 -0.69
30,254
96.94M
US$ 139.590M
US$ 21.79
0.08 0.37
6,066
6.33M
US$ 137.930M
US$ 5.61
0.05 0.90
58,470
24.49M
US$ 137.390M
C$ 0.47
0.005 1.08
59,122
278.58M
C$ 130.930M
US$ 4.02
0.00 0.00
49,808
31.62M
US$ 127.110M
US$ 5.09
0.48 10.41
760,110
22.92M
US$ 116.660M
US$ 2.20
0.00 0.00
366,262
50.51M
US$ 111.120M
US$ 2.28
0.13 5.81
406,167
45.71M
US$ 103.990M
US$ 1.85
-0.03 -1.60
163,670
54.98M
US$ 101.710M
US$ 3.50
0.17 5.11
123,266
28.49M
US$ 99.720M
US$ 5.25
-0.20 -3.67
48,962
16.64M
US$ 87.360M
US$ 1.76
-0.11 -5.88
20,132
47.69M
US$ 83.930M
US$ 3.91
-0.14 -3.46
133,741
19.55M
US$ 76.440M
US$ 1.98
-0.04 -1.98
12,121
38.21M
US$ 75.660M
US$ 2.31
0.03 1.32
51,637
31.63M
US$ 73.070M
US$ 0.70
0.00 0.00
101,915
102.68M
US$ 71.880M
US$ 5.28
-0.18 -3.30
85,544
13.32M
US$ 70.330M
US$ 2.46
-0.03 -1.20
43,464
27.29M
US$ 67.130M
US$ 3.27
0.05 1.40
4,542
19.96M
US$ 65.270M
US$ 1.27
0.02 1.60
87,181
51.23M
US$ 65.060M
US$ 3.92
-0.07 -1.75
46,020
16.39M
US$ 64.250M
US$ 0.23
0.004 1.74
1.13M
271.99M
US$ 63.650M
US$ 1.74
0.05 2.96
230,516
36.04M
US$ 62.710M
US$ 3.50
0.00 0.00
0
17.64M
US$ 61.740M
US$ 17.41
0.19 1.10
4,326
3.51M
US$ 61.110M
US$ 1.93
0.01 0.52
33,346
31.63M
US$ 61.050M
US$ 1.95
0.01 0.52
105,717
30.99M
US$ 60.430M
US$ 1.09
0.05 4.81
1.71M
54.69M
US$ 59.610M
US$ 2.22
0.04 1.83
81,370
26.33M
US$ 58.450M
US$ 0.74
-0.01 -1.43
574,125
78.69M
US$ 58.160M
US$ 1.00
-0.07 -6.54
182,369
56.84M
US$ 56.840M
C$ 0.86
0.01 1.18
2,442
65.03M
C$ 55.930M
C$ 0.50
0.04 8.70
35,150
109.27M
C$ 54.640M
US$ 1.19
0.01 0.85
99,397
45.73M
US$ 54.420M
US$ 2.28
0.03 1.40
25,039
23.46M
US$ 53.530M
US$ 2.57
0.00 0.00
0
20.76M
US$ 53.350M
US$ 0.93
0.04 4.48
84,229
54.29M
US$ 50.480M
US$ 1.41
0.13 10.16
301,783
34.64M
US$ 48.840M
US$ 0.63
0.0025 0.40
45,665
76.19M
US$ 47.960M
US$ 2.95
0.44 17.53
257,413
16.25M
US$ 47.940M
US$ 0.99
0.00 0.00
491,288
48.00M
US$ 47.520M
US$ 0.29
-0.03 -8.88
874,562
156.13M
US$ 45.640M
US$ 3.76
0.22 6.21
14,198
11.40M
US$ 42.860M
US$ 1.50
-0.02 -0.99
139,399
27.79M
US$ 41.680M
C$ 0.41
0.03 7.89
56,730
101.40M
C$ 41.570M
US$ 4.28
-0.19 -4.25
22,557
8.96M
US$ 38.350M
US$ 0.52
0.0057 1.12
109,995
73.93M
US$ 38.210M
C$ 0.32
0.00 0.00
0
118.47M
C$ 37.910M
C$ 0.17
-0.02 -8.33
92,000
228.46M
C$ 37.700M
US$ 0.99
0.01 1.09
36,121
37.19M
US$ 36.820M
US$ 1.20
0.02 1.27
63,769
29.94M
US$ 35.780M
US$ 3.45
-0.06 -1.57
24,309
10.34M
US$ 35.620M
C$ 0.23
-0.005 -2.17
71,200
156.82M
C$ 35.280M
US$ 5.87
-0.29 -4.71
33,611
6.00M
US$ 35.220M
US$ 1.11
-0.005 -0.45
39,499
31.26M
US$ 34.700M
US$ 2.12
-0.08 -3.64
662,281
16.29M
US$ 34.530M
US$ 1.47
-0.03 -2.00
887,719
21.65M
US$ 31.830M
US$ 1.21
0.05 3.88
261,523
25.93M
US$ 31.250M
US$ 1.39
-0.02 -1.42
1.10M
19.96M
US$ 27.740M
US$ 0.07
-0.0005 -0.70
206,551
389.89M
US$ 27.680M
C$ 0.30
0.00 0.00
18,500
90.89M
C$ 27.270M
US$ 1.56
0.02 1.30
47,411
17.24M
US$ 26.890M
US$ 1.42
-0.07 -4.70
68,532
17.90M
US$ 25.420M
US$ 1.76
-0.04 -2.22
137,073
14.00M
US$ 24.640M
US$ 0.02
0.0011 5.37
585,900
1.14B
US$ 24.580M
US$ 0.71
0.06 9.08
430,402
34.62M
US$ 24.550M
US$ 2.27
0.06 2.71
226
10.54M
US$ 23.930M
C$ 0.34
0.005 1.49
500
69.23M
C$ 23.540M
US$ 2.08
-0.01 -0.48
49,466
11.13M
US$ 23.150M
C$ 0.43
-0.005 -1.15
7,128
52.67M
C$ 22.650M
C$ 0.12
0.005 4.55
40,000
194.28M
C$ 22.340M
US$ 0.40
-0.72 -64.46
14,376
55.68M
US$ 22.040M
US$ 2.73
0.67 32.52
435,791
8.05M
US$ 21.980M
US$ 0.98
0.02 2.05
86,549
21.30M
US$ 20.870M
US$ 0.99
-0.02 -1.97
15,846
20.36M
US$ 20.160M
US$ 0.78
0.04 5.23
20,939
25.08M
US$ 19.560M
US$ 0.69
0.00 0.00
781,484
27.87M
US$ 19.230M
US$ 1.07
0.04 3.88
39,154
16.77M
US$ 17.940M
US$ 3.00
0.0001 0.00
2,907
5.80M
US$ 17.400M
US$ 1.15
0.03 2.22
29,025
14.40M
US$ 16.560M
US$ 8.88
-0.12 -1.33
3,246
1.82M
US$ 16.150M
US$ 2.75
0.28 11.34
655,323
5.85M
US$ 16.090M
US$ 2.75
0.02 0.64
24,347
5.74M
US$ 15.780M
US$ 0.44
-0.02 -3.28
68,365
35.05M
US$ 15.590M
US$ 3.05
0.19 6.64
267,315
4.93M
US$ 15.040M
US$ 0.89
0.00 0.00
62,458
16.82M
US$ 14.970M
US$ 0.45
0.01 2.74
78,856
29.98M
US$ 13.490M
C$ 0.07
0.00 0.00
15,000
188.08M
C$ 13.170M
US$ 4.45
0.18 4.22
42,041
2.84M
US$ 12.640M
US$ 1.35
0.02 1.50
16,642
9.26M
US$ 12.500M
C$ 0.13
0.00 0.00
14,500
99.64M
C$ 12.460M
US$ 2.79
0.12 4.31
9,852
4.06M
US$ 11.310M
US$ 2.81
0.10 3.69
35,850
3.85M
US$ 10.820M
US$ 0.62
-0.01 -2.17
74,219
17.39M
US$ 10.720M
US$ 1.01
-0.04 -3.81
58,625
10.04M
US$ 10.140M
US$ 0.82
-0.15 -15.74
320,346
11.04M
US$ 9.060M
US$ 0.12
0.00 0.00
0
73.90M
US$ 8.870M
US$ 0.75
0.25 50.00
100
11.77M
US$ 8.830M
US$ 6.20
0.12 1.97
3,328
1.42M
US$ 8.810M
C$ 0.12
-0.005 -4.00
10,000
71.31M
C$ 8.560M
US$ 4.16
0.16 4.00
2,561
1.99M
US$ 8.280M
US$ 1.33
0.06 4.72
20,470
6.19M
US$ 8.230M
US$ 0.12
-0.0028 -2.34
773,634
65.56M
US$ 7.680M
US$ 0.45
0.01 3.05
62,467
16.98M
US$ 7.620M
C$ 0.08
0.00 0.00
0
94.47M
C$ 7.560M
US$ 0.72
-0.03 -4.33
3.15M
10.01M
US$ 7.180M
US$ 0.11
-0.12 -53.91
33,153
66.78M
US$ 7.080M
US$ 0.73
0.26 55.32
310,991
9.33M
US$ 6.810M
C$ 0.06
0.005 10.00
238,979
122.72M
C$ 6.750M
C$ 0.12
0.00 0.00
0
54.90M
C$ 6.590M
US$ 4.65
0.18 4.03
45,495
1.33M
US$ 6.180M
US$ 0.20
0.0001 0.05
1.43M
29.30M
US$ 5.800M
US$ 0.78
0.16 25.81
472,880
7.29M
US$ 5.690M
US$ 0.02
0.00 0.00
0
286.49M
US$ 5.590M
US$ 0.35
-0.0021 -0.60
94,017
15.27M
US$ 5.280M
US$ 2.94
-0.005 -0.17
5,451
1.70M
US$ 5.000M
US$ 5.60
0.02 0.36
4,905
886,743
US$ 4.970M
US$ 0.72
0.01 2.11
22,416
6.36M
US$ 4.580M
US$ 1.71
-0.04 -2.29
6,739
2.62M
US$ 4.480M
US$ 0.18
-0.0008 -0.44
109,090
23.46M
US$ 4.250M
C$ 0.02
-0.005 -25.00
4,000
246.29M
C$ 3.690M
US$ 0.19
0.03 19.21
9.75M
19.20M
US$ 3.670M
US$ 0.49
-0.0001 -0.02
8,856
7.03M
US$ 3.440M
US$ 1.10
0.09 8.91
18,555
2.49M
US$ 2.740M
US$ 0.03
-0.002 -5.71
298,798
83.12M
US$ 2.740M
US$ 0.39
-0.02 -3.95
144,069
6.80M
US$ 2.680M
US$ 0.02
0.00 0.00
0
161.02M
US$ 2.580M
C$ 0.05
0.005 11.11
23,000
48.23M
C$ 2.410M
US$ 0.90
-0.05 -5.74
98,249
2.60M
US$ 2.340M
US$ 0.08
-0.03 -23.93
4,605
28.90M
US$ 2.310M
US$ 0.25
0.01 5.71
450,570
9.09M
US$ 2.270M
US$ 0.70
-0.0025 -0.36
11,896
3.14M
US$ 2.190M
US$ 0.45
0.01 2.78
826
4.88M
US$ 2.180M
US$ 0.42
-0.02 -4.28
69,076
5.03M
US$ 2.090M
US$ 0.93
0.03 3.56
16,747
2.05M
US$ 1.910M
US$ 2.15
0.05 2.38
15,720
879,176
US$ 1.890M
US$ 1.19
-0.01 -0.83
38,556
1.47M
US$ 1.750M
C$ 0.01
0.00 0.00
1.02M
160.81M
C$ 1.610M
US$ 0.80
-0.0076 -0.94
31,995
1.78M
US$ 1.430M
US$ 0.10
0.04 63.93
3,650
9.74M
US$ 974K
US$ 0.0007
-0.0002 -22.22
300,000
463.12M
US$ 324K
US$ 5.18
0.00 0.00
27,125
-
US$ -
US$ 3.57
0.01 0.28
121,010
-
US$ -
US$ 0.41
0.00 0.00
0
-
US$ -
C$ 1.30
0.00 0.00
363,305
-
C$ -
C$ 0.22
0.00 0.00
37,967
-
C$ -

Latest News From Medical Stocks


Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Results indicate potential of a minimally invasive screening tool to detect most common form of Esophageal Cancer, a highly treatable cancer if caught early MADISON, Wis. / Mar 28, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard® Esophagus test... Read more


DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results

Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased. 2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction. Commercial revenues in 2023 generated majority of the revenue with B2B2C growing from 13% to 25% of total revenue from 2022 to 2023. GAAP operating... Read more


NeuroPace to Present at the Needham 23rd Annual Healthcare Conference

MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will present at the Needham 23rd Annual Healthcare Conference, taking place virtually from April 8-11. Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Monday, April 8 at 3:45pm ET, and management will participate in one-on-one meetings... Read more


Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

BEVERLY, Mass. and TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX: HTL), a leading provider of precision instruments, laboratory equipment, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported audited financial results for the fourth quarter and year-ended December 31, 2023. Financial Highlights Sales for the year increased 16% to $67.2 million; sales for the quarter... Read more


NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

Insights from 11 Abstracts Highlight Key Findings Across the Oncology Care Spectrum FT. MYERS, Fla. / Mar 27, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through... Read more


Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut... Read more


Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes

HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif., March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the University of Tartu, host of Estonia's... Read more


MiMedx Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced... Read more


Novocure: METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell...

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT ROOT, Switzerland / Mar 27, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant... Read more


Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Presentations Will Feature Studies Evaluating TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution) and enVista® Envy* and IC-8® Apthera™ IOLs VAUGHAN, Ontario / Mar 27, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced fifteen podium and four poster presentations during the American Society of Cataract and Refractive... Read more


EDAP TMS Reports Fourth Quarter and Full-Year 2023 Financial Results

Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022 Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022 Record full-year 2023 total revenue of EUR 60.4 million ($65.4 million USD) increased 9.6% over full-year 2022 Record full-year 2023 HIFU revenue of EUR 20.6 million ($22.3 million USD), an increase of 31.7% over full-year 2022 Strong Q4 2023 U.S. Focal One® HIFU procedure... Read more


Castle Biosciences Announces Updates to its Board of Directors

FRIENDSWOOD, Texas / Mar 27, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Rodney Cotton has been appointed to its board of directors, effective immediately, and will stand for election at Castle’s 2024 Annual Meeting of Stockholders, expected to be held in May 2024. The Company further announced that Mara G. Aspinall will not stand for re-election to its... Read more


Theralase Technologies Release's 4Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated Photo Dynamic Compounds ("PDCs") for the safe and effective destruction of various cancers, bacteria and viruses has released the Company's audited annual consolidated 2023 financial statements ("Financial Statements"). Theralase®... Read more


Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI®-Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and Diabetic Foot Ulcer Indications DALLAS, March 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial... Read more


STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter and Full-Year 2023 and Recent Business Highlights: Revenue in the fourth quarter... Read more


PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

Lucid's quarterly revenue increased 33 percent sequentially Launched wholly-owned incubator, PMX, to complete development and commercialization of existing portfolio technologies Conference call and webcast to be held tomorrow, March 27th at 8:30 AM ET NEW YORK, March 26, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics,... Read more


LeMaitre Vascular to Present at the 23rd Annual Needham Virtual Healthcare Conference

BURLINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present virtually at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 11:30 AM ET. About LeMaitre LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company... Read more


Stevanato Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters’ Option to Purchase Additional Ordinary Shares

PIOMBINO DESE, Italy / Mar 26, 2024 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the... Read more


Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually. Sight Sciences’ management is scheduled to present on Tuesday,... Read more


NeuroOne Medical Technologies Initiates Limited Commercial Launch of OneRF™ Ablation System

First to market FDA-cleared thin-film, sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue with the added benefit of temperature control Limited commercial launch initiated earlier than expected EDEN PRAIRIE, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and... Read more


HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Pati

Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the podium presentation of a study utilizing its MyoVista® wavECG device at the 18th World Congress of Anesthesiologists in Sing... Read more


Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City. LD Micro Invitational XIV Investment ConferenceDates:... Read more


TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting

New safety and feasibility data from Phase 1/1b PERIO-03 trial for locally advanced pancreatic cancer supports further development of the novel TriSalus Infusion System for therapeutic delivery via retrograde venous delivery  A retrospective clinical study of the Pressure-Enabled Drug Delivery™ (PEDD™) method supports selection of the TriNav® Infusion System for treatment-refractory hypovascular tumors  DENVER & SALT LAKE CITY / Mar 26, 2024 / Business... Read more


Tenon Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System

Preliminary SI Joint Fusion Results Based on Independent Radiologist Review Indicate Robust Fusion at 12-Months Post-Procedure Initial Patient Results Demonstrate Marked Improvements in Pain Scores and Disability, Along with High Patient Satisfaction Ratings LOS GATOS, CA / ACCESSWIRE / March 26, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac joint disorders, today announced... Read more


Genetic Technologies Global Collaborations and Innovation Update

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groups Continuous development of the geneType portfolio A deep pipeline of new unique and... Read more


Accuray: New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis., March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years... Read more


Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs SECAUCUS, N.J., March 26, 2024 /PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease (AD) is likely not the cause of patients'... Read more


InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being... Read more


Modular Medical Announces Steve Gemmell as New Vice President of Engineering

SAN DIEGO, CA / ACCESSWIRE / March 26, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the addition of Steve Gemmell as Vice President of Engineering. Gemmell has over 20 years of experience in medical device product development and operations and previously held R&D... Read more


Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y., March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. Recent Business Highlights During and since the fourth... Read more


Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenatide implant) preclinical weight loss data comparable to semaglutide, active ingredient in Ozempic®/Wegovy® $15 million financing round enables acceleration of priority development programs and secures operations into the second half of 2025 ALAMEDA, Calif. / Mar 26, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI)... Read more


Iridex Reports Fourth Quarter and Full Year 2023 Financial Results

MOUNTAIN VIEW, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended December 30, 2023, and provided a business update. Fourth Quarter 2023 Results & Recent Highlights Generated total revenue... Read more


ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and... Read more


QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective diagnosis of complex syndromes. The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces... Read more


Sanara MedTech Announces Fourth Quarter and Full Year 2023 Results

FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial... Read more


Inspira™ Technologies Reports Full Year 2023 Financial Results

FDA Submission for approval of INSPIRA™ ART100 95% Accuracy Results for HYLA™ Blood Sensor Compared to Standard Blood Gas Analyzers Granted U.S. Patent for INSPIRA™ ART Medical Device RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December... Read more


Inogen To Present at 23rd Annual Needham Virtual Healthcare Conference

GOLETA, Calif. / Mar 25, 2024 / Business Wire / Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 23rd Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 9, 2024, at 9:30 a.m. Eastern... Read more


Neuronetics: NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar Advanced Therapy for use as an adjunct for the treatment of major depressive disorder (MDD) in adolescent patients aged 15-21. NeuroStar... Read more


Genetic Technologies to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

MELBOURNE, Australia, March 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GENE”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to announce the development of the Company’s most advanced risk assessment test for serious diseases, building on the success of the Comprehensive Hereditary Breast and Ovarian Cancer (HBOC) test. GeneType's latest innovation will... Read more


Olink reports fourth quarter and full year 2023 financial results

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023. Highlights Fourth quarter 2023 revenue totaled $68.6 million, representing year over year growth of 18% on a reported basis and 17% on a constant currency adjusted like-for-like basis Full year revenue 2023 revenue totaled $169.6 million, achieving year over year... Read more


Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

LOUISVILLE, Colo. / Mar 25, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize its array of genomics, proteomics,... Read more


Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

First medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – March 25, 2024, 7:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has signed a strategic partnership to become a Corporate... Read more


VolitionRx Announces Full Fiscal Year 2023 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., March 25, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the full fiscal year ended December 31, 2023. Volition management will host a conference call tomorrow, March 26 at 8:30 a.m. U.S. Eastern Time... Read more


Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Quarterly EsoGuard® revenue increased 33 percent sequentially Expanding EsoGuard clinical validity and clinical utility data poised to drive medical policy coverage, including line of sight to Medicare coverage Conference call and webcast to be held tomorrow, March 26th at 8:30 AM ET NEW YORK, March 25, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company,... Read more


Tivic Health Systems Reports Fiscal Year 2023 Financial Results

SAN FRANCISCO / Mar 25, 2024 / Business Wire / Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced its financial results for the year ending December 31, 2023. Tivic’s commercial platform is a handheld design that interfaces non-invasively with the trigeminal, sympathetic, and other facial and cranial nerve structures. This platform is the basis for Tivic’s existing product,... Read more


Justera Health Appoints Tyler Burpee to Board of Directors

Toronto, Ontario--(Newsfile Corp. - March 22, 2024) - Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") announces the appointment of Tyler Burpee to the board of directors and the resignation of director Ian Kim for personal reasons, effective March 21st, 2024. The Company extends its deepest appreciation to Mr. Kim for his service and contributions since his appointment to the board of directors on December 6, 2023. Mr. Burpee is a seasoned... Read more


Castle Biosciences: Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the...

Castle’s second presentation at SSO 2024 shows that in a study of 979 patients, DecisionDx-Melanoma demonstrated clinical use value in patients with TI cutaneous melanoma (CM), identifying high-risk patients who could consider a more intensive treatment pathway, such as a sentinel lymph node biopsy (SLNB) and imaging surveillance FRIENDSWOOD, Texas / Mar 22, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative... Read more


Sanuwave Health Announces Record Q4 and FY2023 Revenue

Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023 EDEN PRAIRIE, MN, March 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - SANUWAVE... Read more


Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market.  U.S. patent 11,932,910, entitled Combinatorial DNA Screening, covers Myriad’s foundational and proprietary... Read more


TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Reported revenue of $17.0 million in the fourth quarter... Read more

COPYRIGHT ©2023 HEALTH STOCKS HUB